Lab-in-the-loop drug discovery has changed research for some organizations. AI-powered predictions improve continuously through wet-lab feedback, speeding up the path from hypothesis to validated candidates. But for most research teams, the reality looks different.

The field moves fast. New biological AI models emerge constantly, each with different strengths, data requirements, and integration needs. Computational biologists must evaluate and operationalize these models while supporting a growing number of discovery programs, often without the infrastructure or resources to match the demand. Meanwhile, bench scientists bring deep biological expertise to their targets and experiments but lack direct access to the computational tools that could speed up their work. The result is a collaboration bottleneck – not because the science isn’t available, but because the tooling doesn’t support how these teams need to work together.

How does it work?

Amazon Bio Discovery changes this by bringing computational design and wet-lab validation together in one application. The platform provides access to 40+ AI biology models with AI-guided selection. Users can also upload custom models as well as models licensed from third parties.

The system works through what Amazon calls “recipes” – computational workflow pipelines that can be modified in a no-code environment. Here’s how a typical antibody design workflow unfolds:

• Start by exploring the catalog of AI biology models, each specialized for different aspects of antibody design
• Use AI-assisted workflow recommendations to select the right models for your goals
• Generate and customize computational recipes that embed your expertise
• Run experiments with AI agent guidance through key decisions like identifying hotspot residues
• Review AI-generated summaries and pre-filtered candidate lists
• Send validated candidates directly to integrated lab partners
• Receive wet-lab results that automatically flow back to improve the next cycle

For computational biologists, this means building and modifying workflows without managing infrastructure. For bench scientists, it means running multiple experiment versions in parallel rather than waiting for custom solutions. Both roles work from the same system, the same data, and the same results.

Why does it matter?

The platform addresses a persistent scaling problem in drug discovery. Even when computational predictions and wet-lab workflows are running, they often stay disconnected. Manual handoffs introduce delays, make it harder to reproduce experiments, and slow the feedback loop that makes lab-in-the-loop valuable.

Amazon points to its collaboration with Memorial Sloan Kettering Cancer Center as proof of concept. Using Bio Discovery, the team designed nearly 300,000 novel antibody candidates, filtered down to the top 100,000, and sent them to the wet lab for testing in weeks versus up to a year using traditional design methods.

The collaboration benefits compound over time:

• Computational biologists create reusable workflows that scale their expertise across multiple programs
• Bench scientists apply specialized knowledge of target biology without waiting in queues
• Results flow back to refine models, making workflows more accurate with each cycle
• Projects that would have been delayed move forward immediately

The context

Amazon’s entry into computational drug discovery comes as pharmaceutical companies increasingly rely on AI to speed up research. The company says 19 of the top 20 pharmaceutical companies already use AWS infrastructure, giving it an existing foothold in the industry.

The platform integrates with established contract research organizations including Ginkgo Bioworks, Twist Bioscience, and A-Alpha Bio. Users can select assays and get cost and turnaround time estimates in real-time, eliminating manual handoffs between computational and experimental work.

Amazon Bio Discovery is available today with enterprise-grade security and data isolation. The company offers a free trial and digital training course for teams looking to implement lab-in-the-loop workflows.

The bigger question is whether Amazon’s no-code approach can actually bridge the gap between computational biologists and bench scientists – or if it just adds another layer of complexity to an already complicated process. The Memorial Sloan Kettering results suggest it works, but one collaboration doesn’t prove the platform will scale across different research contexts and organizational structures.